For research use only. Not for therapeutic Use.
Crenigacestat(CAT: I001625) is a potent gamma-secretase inhibitor with significant applications in oncology research. By targeting the Notch signaling pathway, it suppresses the cleavage of Notch receptors, effectively downregulating their activity. This inhibition disrupts tumorigenesis by preventing abnormal cell differentiation and proliferation. Crenigacestat is instrumental in studies focused on solid tumors and hematological malignancies, offering insights into therapeutic interventions targeting Notch-mediated pathways. Its specificity and efficacy make it a valuable tool in cancer-related drug development, aiding researchers in exploring novel therapeutic strategies. Crenigacestat integrates seamlessly into experimental protocols, supporting advancements in oncology and personalized medicine research.
Catalog Number | I001625 |
CAS Number | 1421438-81-4 |
Synonyms | LY3039478; LY 3039478; LY-3039478; 4,4,4-trifluoro-N-[(2S)-1-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide |
Molecular Formula | C22H23F3N4O4 |
Purity | ≥95% |
Target | Stem Cell/Wnt |
Solubility | DMSO ≥ 35 mg/mL |
Storage | 3 years -20°C powder |
IUPAC Name | 4,4,4-trifluoro-N-[(2S)-1-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide |
InChI | InChI=1S/C22H23F3N4O4/c1-13(27-17(31)8-9-22(23,24)25)20(32)28-18-15-6-3-2-5-14(15)16-7-4-10-26-19(16)29(11-12-30)21(18)33/h2-7,10,13,18,30H,8-9,11-12H2,1H3,(H,27,31)(H,28,32)/t13-,18-/m0/s1 |
InChIKey | YCBAQKQAINQRFW-UGSOOPFHSA-N |
SMILES | O=C(N[C@@H](C)C(N[C@H]1C2=CC=CC=C2C3=CC=CN=C3N(CCO)C1=O)=O)CCC(F)(F)F |